Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1
NCT ID: NCT00000320
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
120 participants
INTERVENTIONAL
1997-10-31
1999-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Liquid vs. Tablet Buprenorphine - 6
NCT00000341
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
NCT01136356
Buprenorphine Combination Tablet Feasibility - 1
NCT00000298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1; liquid formulation
liquid formulation
Buprenorphine formulation: liquid vs. tablet
random assignment to liquid buprenorphine or tablet buprenorphine
2; tablet formulation
tablet formulation
Buprenorphine formulation: liquid vs. tablet
random assignment to liquid buprenorphine or tablet buprenorphine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Buprenorphine formulation: liquid vs. tablet
random assignment to liquid buprenorphine or tablet buprenorphine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Friends Research Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Walter Ling, M.D.
Role: PRINCIPAL_INVESTIGATOR
Friends Research Institute, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Friends Research Institute
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01-10068-1
Identifier Type: -
Identifier Source: secondary_id
NIDA-10068-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.